Просмотр новости
Найдите то, что Вас интересует
Спутники
РН
SpaceX
Роскосмос
NASA
СпутникиРНSpaceXРоскосмосNASAEvidence for efficacy is based on the results from the PSMAddition study
Login to your ESMO Account to sign up for ESMO newsletters and receive information about ESMO's scientific and educational resources, events, member benefits.
ESMO is a Swiss-registered not-for-profit organisation. All funding for this site is provided directly by ESMO. Via Ginevra 4, 6900 Lugano - CH
© Copyright 2026 European Society for Medical Oncology All rights reserved worldwide.
| # | Наименование новости | Тональность | Информативность | Дата публикации |
|---|---|---|---|---|
| 1 | FDA grants accelerated approval to vusolimogene oderparepvec-wtpg in combination with nivolumab for melanoma | 0 | 12.14 | 30-09-2026 |
| 2 | EMA recommends extension of indications for pirtobrutinib | 0 | 8.86 | 25-09-2026 |
| 3 | FDA OKs Lyrfigtu for previously treated bile duct cancer | 0 | 11.23 | 23-09-2026 |
| 4 | EMA Recommends Granting a Marketing Authorisation for Ensartinib | 0 | 13.61 | 09-10-2026 |
| 5 | FDA approves Welireg-Lenvima combination for advanced RCC | 0 | 10.87 | 24-09-2026 |
| 6 | Jemperli (dostarlimab) accepted for priority review by the US FDA for dMMR/MSI-H locally advanced rectal cancer | 0 | 9.74 | 24-08-2026 |
| 7 | FDA grants accelerated approval to iberdomide with daratumumab and hyaluronidase-fihj and dexamethasone for multiple myeloma | 0 | 15.43 | 07-10-2026 |
| 8 | EMA recommends granting a marketing authorisation for relacorilant | 0 | 9.25 | 02-10-2026 |
| 9 | В России зарегистрировали препарат для лечения рака груди | 0 | 10.99 | 06-10-2026 |